VOLUME 16 - NUMBER 3 / May - June (Review article / Artículo de revisión)
Miguel Quintana-Quintana, Department of Medical Oncology, Hospital General Naval de Alta Especialidad, Coyoacán, Ciudad de México, Mexico
Consuelo Díaz-Romero, Servicio de Oncología Médica, Instituto Nacional de Cancerología, Ciudad de México, México
Christian Patricio Camacho-Limas, Department of Medical Oncology, Centro Médico ABC, Mexico City, Mexico
Laura Torrecillas-Torres, Servicio de Oncología Médica, Centro Médico Nacional 20 de Noviembre, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad de México, México
Erika Ruiz-García, Department of Medical Oncology, Instituto Nacional de Cancerología, Mexico City; Department of Medical Oncology, Centro Oncológico Privado, Mexico City; Mexico
José Antonio Acevedo-Delgado, Medicina Privada, Guadalajara, Jal., Mexico
Guillermo Olivares-Beltrán, Department of Medical Oncology, Centro Médico ABC, Mexico City, Mexico
Francisco Medina-Soto, Centro de Especialidades Médicas, Monterrey, N.L., Mexico
Jorge Alberto Robles-Aviña, Hospital Central Sur de Alta Especialidad PEMEX, Mexico City, Mexico
Pedro Sobrevilla, Hospital Ángeles del Pedregal, Mexico City, Mexico
Juan Cruz-Baca, Hospital Christus Muguerza, Mexico City, Mexico
Alicia Espinoza-Acosta, Hospital General 5 de Diciembre, ISSSTE, Mexicali, B.C., Mexico
Daniel Motola-Kuba, Hospital Médica Sur, Mexico City, Mexico
Ramiro Magaña-Serrano, Centro Médico de Especialidades, Cd. Juárez, Chih., Mexico
Juan Paulo Ceja-García, Hospital General, La Paz, B.C.S., Mexico
Alejandro Molina-Franco, Oncología Médica, Mérida, Yuc., Mexico
Leticia Vázquez-Cortes, Hospital General de México, Mexico City, Mexico
Julia A. Sáenz-Frías, Departamento de Radio-Oncología, Centro Médico del Noreste, Unidad Médica de Alta Especialidad 25, IMSS, Monterrey, N.L., México
Iván Romerico González-Espinoza, Hospital Ángeles, Puebla, Pue., Mexico
Eduardo Téllez-Bernal, Servicio de Oncología, ISSSTEP; Unidad Médica Oncológica; Puebla, México
Eva Lucia Willars-Inman, ISSSTE, Saltillo, Coah., Mexico
Luis J. Barajas-Figueroa, Departamento de Cirugía, Centro de Alta Especialidad en Oncología San José, Hermosillo, Son., México
Flor de Thé Bustamante-Valles, COC Centro Oncológico de Chihuahua, Cd. Juárez, Chih., Mexico
Benjamín Dávalos-Félix, Práctica Privada, Monterrey, N.L., Mexico
Saúl Campos-Gómez, Departamento de Oncología Médica, Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Edo. de México, México
Germán Calderillo-Ruiz, Servicio de Oncología Médica, Instituto Nacional de Cancerología, Ciudad de México, México
Abstract In the last years, there has been an improvement in the overall survival of patients with gastrointestinal tumors, one of the main factors being the deep understanding of molecular biology, the determination of prognostic factors, and of course, the development of new drugs all in has allowed gradual but significant advances in the treatment of gastric cancer. The first-line of treatment has shown benefits, however many of these patients show progression of the disease, which raises the challenge of optimizing the following treatment lines, and developing better treatment strategies. The role of second-line treatment has recently been introduced and discussed, although there is evidence regarding the benefit of some drugs such as docetaxel, paclitaxel and irinotecan in second-line treatment, and this benefit has shown a reduction in the risk of death of approximately 18%, there is still a need to discuss and analyze the efficacy in overall survival, progression free period, toxicity profile, and with special emphasis on the appropriate choice of drugs according to efficacy, toxicity, prognostic factors and characteristics of patients. The objective of this cross-sectional study is to analyze the medical experience in real clinical practice in the scenario of second-line treatment for metastatic gastric cancer in patients treated with ramucirumab, as well as to analyze prognostic factors and their impact on daily clinical practice.
Keywords: Gastric Cancer. Stomach cancer. Gastric cancer with metastasis. Advanced gastric cancer. Ramucirumab. Second line. Antiangiogenic. Real world evidence.
